Full length stripping of the long saphenous vein below the knee is no longer recommended due to its relation to the saphenous nerve, while the short saphenous vein is related to the sural nerve.

The Anatomy of Saphenous Veins

The human body has two saphenous veins: the long saphenous vein and the short saphenous vein. The long saphenous vein is often used for bypass surgery or removed as a treatment for varicose veins. It originates at the first digit where the dorsal vein merges with the dorsal venous arch of the foot and runs up the medial side of the leg. At the knee, it runs over the posterior border of the medial epicondyle of the femur bone before passing laterally to lie on the anterior surface of the thigh. It then enters an opening in the fascia lata called the saphenous opening and joins with the femoral vein in the region of the femoral triangle at the saphenofemoral junction. The long saphenous vein has several tributaries, including the medial marginal, superficial epigastric, superficial iliac circumflex, and superficial external pudendal veins.

On the other hand, the short saphenous vein originates at the fifth digit where the dorsal vein merges with the dorsal venous arch of the foot, which attaches to the great saphenous vein. It passes around the lateral aspect of the foot and runs along the posterior aspect of the leg with the sural nerve. It then passes between the heads of the gastrocnemius muscle and drains into the popliteal vein, approximately at or above the level of the knee joint.

Understanding the anatomy of saphenous veins is crucial for medical professionals who perform surgeries or treatments involving these veins.

The heart is supplied with blood by the coronary arteries, which branch off from the aorta. The right coronary artery supplies blood to the right side of the heart, while the left coronary artery supplies blood to the left side of the heart.

Occlusion, or blockage, of the right coronary artery can cause inferior myocardial infarction (MI), which is indicated on an electrocardiogram (ECG) by changes in leads II, III, and aVF. This type of MI is particularly associated with arrhythmias because the right coronary artery usually supplies the sinoatrial (SA) and atrioventricular (AV) nodes.

The left anterior descending artery (LAD) is one of the two branches of the left coronary artery. It runs along the front of the heart’s interventricular septum to reach the apex of the heart. One or more diagonal branches may arise from the LAD. Occlusion of the LAD can cause anteroseptal MI, which is evident on an ECG with changes in leads V1-V4.

The right marginal artery branches off from the right coronary artery near the bottom of the heart and continues along the heart’s bottom edge towards the apex.

The left circumflex artery is the other branch of the left coronary artery. It runs in the coronary sulcus around the base of the heart and gives rise to the left marginal artery. Occlusion of the left circumflex artery is typically associated with lateral MI.

The left marginal artery arises from the left circumflex artery and runs along the heart’s obtuse margin.

The walls of each cardiac chamber are made up of the epicardium, myocardium, and endocardium. The heart and roots of the great vessels are related anteriorly to the sternum and the left ribs. The coronary sinus receives blood from the cardiac veins, and the aortic sinus gives rise to the right and left coronary arteries. The left ventricle has a thicker wall and more numerous trabeculae carnae than the right ventricle. The heart is innervated by autonomic nerve fibers from the cardiac plexus, and the parasympathetic supply comes from the vagus nerves. The heart has four valves: the mitral, aortic, pulmonary, and tricuspid valves.

Rapid depolarization is caused by a rapid influx of sodium.

During phase 2, the plateau period, calcium influx is responsible.

To maintain the electrical gradient, there is potassium influx in phase 4, which is facilitated by inward rectifying K+ channels and the Na+/K+ ion exchange pump.

Potassium efflux mainly occurs during phases 1 and 3.

Understanding the Cardiac Action Potential and Conduction Velocity

The cardiac action potential is a series of electrical events that occur in the heart during each heartbeat. It is responsible for the contraction of the heart muscle and the pumping of blood throughout the body. The action potential is divided into five phases, each with a specific mechanism. The first phase is rapid depolarization, which is caused by the influx of sodium ions. The second phase is early repolarization, which is caused by the efflux of potassium ions. The third phase is the plateau phase, which is caused by the slow influx of calcium ions. The fourth phase is final repolarization, which is caused by the efflux of potassium ions. The final phase is the restoration of ionic concentrations, which is achieved by the Na+/K+ ATPase pump.

Conduction velocity is the speed at which the electrical signal travels through the heart. The speed varies depending on the location of the signal. Atrial conduction spreads along ordinary atrial myocardial fibers at a speed of 1 m/sec. AV node conduction is much slower, at 0.05 m/sec. Ventricular conduction is the fastest in the heart, achieved by the large diameter of the Purkinje fibers, which can achieve velocities of 2-4 m/sec. This allows for a rapid and coordinated contraction of the ventricles, which is essential for the proper functioning of the heart. Understanding the cardiac action potential and conduction velocity is crucial for diagnosing and treating heart conditions.

The inferior pancreatico-duodenal artery is the first branch of the SMA, which exits the aorta at L1 and travels beneath the neck of the pancreas.

The Superior Mesenteric Artery and its Branches

The superior mesenteric artery is a major blood vessel that branches off the aorta at the level of the first lumbar vertebrae. It supplies blood to the small intestine from the duodenum to the mid transverse colon. However, due to its more oblique angle from the aorta, it is more susceptible to receiving emboli than the coeliac axis.

The superior mesenteric artery is closely related to several structures, including the neck of the pancreas superiorly, the third part of the duodenum and uncinate process postero-inferiorly, and the left renal vein posteriorly. Additionally, the right superior mesenteric vein is also in close proximity.

The superior mesenteric artery has several branches, including the inferior pancreatico-duodenal artery, jejunal and ileal arcades, ileo-colic artery, right colic artery, and middle colic artery. These branches supply blood to various parts of the small and large intestine. An overview of the superior mesenteric artery and its branches can be seen in the accompanying image.

Understanding the Cardiac Action Potential and Conduction Velocity

The cardiac action potential is a series of electrical events that occur in the heart during each heartbeat. It is responsible for the contraction of the heart muscle and the pumping of blood throughout the body. The action potential is divided into five phases, each with a specific mechanism. The first phase is rapid depolarization, which is caused by the influx of sodium ions. The second phase is early repolarization, which is caused by the efflux of potassium ions. The third phase is the plateau phase, which is caused by the slow influx of calcium ions. The fourth phase is final repolarization, which is caused by the efflux of potassium ions. The final phase is the restoration of ionic concentrations, which is achieved by the Na+/K+ ATPase pump.

Conduction velocity is the speed at which the electrical signal travels through the heart. The speed varies depending on the location of the signal. Atrial conduction spreads along ordinary atrial myocardial fibers at a speed of 1 m/sec. AV node conduction is much slower, at 0.05 m/sec. Ventricular conduction is the fastest in the heart, achieved by the large diameter of the Purkinje fibers, which can achieve velocities of 2-4 m/sec. This allows for a rapid and coordinated contraction of the ventricles, which is essential for the proper functioning of the heart. Understanding the cardiac action potential and conduction velocity is crucial for diagnosing and treating heart conditions.

Patients with reduced ejection fraction heart failure (HF-rEF) usually experience systolic dysfunction, which refers to the impaired ability of the myocardium to contract during systole.

Types of Heart Failure

Heart failure is a clinical syndrome where the heart cannot pump enough blood to meet the body’s metabolic needs. It can be classified in multiple ways, including by ejection fraction, time, and left/right side. Patients with heart failure may have a normal or abnormal left ventricular ejection fraction (LVEF), which is measured using echocardiography. Reduced LVEF is typically defined as < 35 to 40% and is termed heart failure with reduced ejection fraction (HF-rEF), while preserved LVEF is termed heart failure with preserved ejection fraction (HF-pEF). Heart failure can also be described as acute or chronic, with acute heart failure referring to an acute exacerbation of chronic heart failure. Left-sided heart failure is more common and may be due to increased left ventricular afterload or preload, while right-sided heart failure is caused by increased right ventricular afterload or preload. High-output heart failure is another type of heart failure that occurs when a normal heart is unable to pump enough blood to meet the body's metabolic needs. By classifying heart failure in these ways, healthcare professionals can better understand the underlying causes and tailor treatment plans accordingly. It is important to note that many guidelines for the management of heart failure only cover HF-rEF patients and do not address the management of HF-pEF patients. Understanding the different types of heart failure can help healthcare professionals provide more effective care for their patients.

The correct answer is increased left ventricular afterload. HFpEF, which is characterized by diastolic dysfunction, often develops due to prolonged systemic hypertension, leading to increased afterload on the left ventricle.

Glomerular hyper-filtration is not the correct answer as heart failure leads to decreased renal perfusion pressure and glomerular hypo-filtration.

Increased left ventricular compliance is also not the correct answer as diastolic dysfunction involves a decrease in LV compliance. LV compliance may increase with eccentric hypertrophy, which occurs in response to left ventricular volume overload.

Left ventricular thrombus formation is not typically associated with diastolic dysfunction and HFpEF. It typically results from localized stagnation of blood, which can occur with a left ventricular aneurysm or in the setting of a severely dilated left ventricle cavity with systolic dysfunction.

Types of Heart Failure

Heart failure is a clinical syndrome where the heart cannot pump enough blood to meet the body’s metabolic needs. It can be classified in multiple ways, including by ejection fraction, time, and left/right side. Patients with heart failure may have a normal or abnormal left ventricular ejection fraction (LVEF), which is measured using echocardiography. Reduced LVEF is typically defined as < 35 to 40% and is termed heart failure with reduced ejection fraction (HF-rEF), while preserved LVEF is termed heart failure with preserved ejection fraction (HF-pEF). Heart failure can also be described as acute or chronic, with acute heart failure referring to an acute exacerbation of chronic heart failure. Left-sided heart failure is more common and may be due to increased left ventricular afterload or preload, while right-sided heart failure is caused by increased right ventricular afterload or preload. High-output heart failure is another type of heart failure that occurs when a normal heart is unable to pump enough blood to meet the body's metabolic needs. By classifying heart failure in these ways, healthcare professionals can better understand the underlying causes and tailor treatment plans accordingly. It is important to note that many guidelines for the management of heart failure only cover HF-rEF patients and do not address the management of HF-pEF patients. Understanding the different types of heart failure can help healthcare professionals provide more effective care for their patients.

Ambrisentan is an antagonist of endothelin-1 receptors, which are involved in vasoconstriction. In pulmonary arterial hypertension (PAH), the expression of endothelin-1 is increased, leading to constriction of blood vessels. Ambrisentan selectively targets ETA receptors found in vascular smooth muscle, reducing morbidity and mortality in PAH patients. Common side effects include peripheral edema, sinusitis, flushing, and nasal congestion. Prostacyclins like PGI2 can also be used to manage PPH by dilating blood vessels and inhibiting platelet aggregation. PGE2, an inflammatory mediator, is not used in PAH treatment. PDE inhibitors like sildenafil increase cGMP levels in pulmonary vessels, relaxing vascular smooth muscle and reducing pulmonary artery pressure.

Pulmonary arterial hypertension (PAH) is a condition where the resting mean pulmonary artery pressure is equal to or greater than 25 mmHg. The pathogenesis of PAH is thought to involve endothelin. It is more common in females and typically presents between the ages of 30-50 years. PAH is diagnosed in the absence of chronic lung diseases such as COPD, although certain factors increase the risk. Around 10% of cases are inherited in an autosomal dominant fashion.

The classical presentation of PAH is progressive exertional dyspnoea, but other possible features include exertional syncope, exertional chest pain, peripheral oedema, and cyanosis. Physical examination may reveal a right ventricular heave, loud P2, raised JVP with prominent ‘a’ waves, and tricuspid regurgitation.

Management of PAH should first involve treating any underlying conditions. Acute vasodilator testing is central to deciding on the appropriate management strategy. If there is a positive response to acute vasodilator testing, oral calcium channel blockers may be used. If there is a negative response, prostacyclin analogues, endothelin receptor antagonists, or phosphodiesterase inhibitors may be used. Patients with progressive symptoms should be considered for a heart-lung transplant.

Amiodarone’s long half-life is due to its high lipophilicity and extensive tissue absorption, resulting in reduced bioavailability in serum. To achieve stable therapeutic levels, a prolonged loading regimen is necessary.

To quickly achieve therapeutic levels, high doses of oral amiodarone are required due to poor absorption. Once achieved, a once-daily regimen can be continued. Amiodarone’s plasma half-life ranges from 20 to 100 days, meaning its effects persist long after discontinuation. Patients should be counseled on this and advised to recognize adverse effects and avoid drugs that interact with amiodarone even after stopping it.

The statement that amiodarone has a short half-life is incorrect; it has a long half-life.

Patients do not need to stay admitted for monitoring during the loading regimen. However, thyroid and liver function tests should be performed every 6 months for up to 12 months after discontinuation due to the long half-life.

Amiodarone is excreted via the liver and biliary system, not rapidly metabolized and eliminated by the kidneys. Therefore, patients with amiodarone overdose or toxicity are not suitable for dialysis.

Amiodarone is a medication used to treat various types of abnormal heart rhythms. It works by blocking potassium channels, which prolongs the action potential and helps to regulate the heartbeat. However, it also has other effects, such as blocking sodium channels. Amiodarone has a very long half-life, which means that loading doses are often necessary. It should ideally be given into central veins to avoid thrombophlebitis. Amiodarone can cause proarrhythmic effects due to lengthening of the QT interval and can interact with other drugs commonly used at the same time. Long-term use of amiodarone can lead to various adverse effects, including thyroid dysfunction, corneal deposits, pulmonary fibrosis/pneumonitis, liver fibrosis/hepatitis, peripheral neuropathy, myopathy, photosensitivity, a ‘slate-grey’ appearance, thrombophlebitis, injection site reactions, and bradycardia. Patients taking amiodarone should be monitored regularly with tests such as TFT, LFT, U&E, and CXR.

Atropine is classified as an antimuscarinic drug that works by inhibiting the M1 to M5 muscarinic receptors. While oxybutynin is commonly prescribed for urinary incontinence due to its ability to block the M3 muscarinic receptors, atropine is more frequently used in anesthesia to reduce salivation before intubation.

Alfuzosin, on the other hand, is an alpha blocker that is primarily used to treat benign prostate hyperplasia.

Meropenem is an antibiotic that is reserved for infections caused by bacteria that are resistant to most beta-lactams. However, it is typically used as a last resort due to its potential adverse effects.

Mirabegron is another medication used to treat urinary incontinence, but it works by activating the β3 adrenergic receptors.

Understanding Atropine and Its Uses

Atropine is a medication that works against the muscarinic acetylcholine receptor. It is commonly used to treat symptomatic bradycardia and organophosphate poisoning. In cases of bradycardia with adverse signs, IV atropine is the first-line treatment. However, it is no longer recommended for routine use in asystole or pulseless electrical activity (PEA) during advanced life support.

Atropine has several physiological effects, including tachycardia and mydriasis. However, it is important to note that it may trigger acute angle-closure glaucoma in susceptible patients. Therefore, it is crucial to use atropine with caution and under the guidance of a healthcare professional. Understanding the uses and effects of atropine can help individuals make informed decisions about their healthcare.